American Association for Cancer Research
10780432ccr203113-sup-249003_2_supp_6854153_q552rc.pdf (38.82 kB)

Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Download (38.82 kB)
journal contribution
posted on 2023-03-31, 23:06 authored by Bruno V. Sinn, Sibylle Loibl, Claus A. Hanusch, Dirk-Michael Zahm, Hans-Peter Sinn, Michael Untch, Karsten Weber, Thomas Karn, Clemens Becker, Frederik Marmé, Wolfgang D. Schmitt, Volkmar Müller, Christian Schem, Denise Treue, Elmar Stickeler, Frederik Klauschen, Nicole Burchardi, Jenny Furlanetto, Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, Carsten Denkert

Patients were randomized to receive one injection durvalumab 0.75 g i.v. or placebo two weeks prior to start of chemotherapy (window trial). This was followed by nab-paclitaxel 125 mg/m2 weekly for 12 weeks with durvalumab 1.5 g i.v. or placebo every 4 weeks. This was followed by epirubicin/cyclophosphamide every two weeks for four cycles with durvalumab or placebo every four weeks. After an amendment, the window phase was stopped, and all patients started with chemotherapy and durvalumab/placebo on day one. Formalin-fixed and paraffin-embedded core biopsy samples were collected prior to randomization (mandatory).


German Cancer Aid



We evaluated mRNA signatures to predict response to neoadjuvant PD-L1 inhibition in combination with chemotherapy in early triple-negative breast cancer. Targeted mRNA sequencing of 2,559 transcripts was performed in formalin-fixed, paraffin-embedded samples from 162 patients of the GeparNuevo trial. We focused on validation of four predefined gene signatures and differential gene expression analyses for new predictive markers. Two signatures [GeparSixto signature (G6-Sig) and IFN signature (IFN-Sig)] were predictive for treatment response in a multivariate model including treatment arm [G6-Sig: OR, 1.558; 95% confidence interval (CI), 1.130–2.182; P = 0.008 and IFN-Sig: OR, 1.695; 95% CI, 1.234–2.376; P = 0.002), while the CYT metric predicted pathologic complete response (pCR) in the durvalumab arm, and the proliferation-associated gene signature in the placebo arm. Expression of PD-L1 mRNA was associated with better response in both arms, indicating that increased levels of PD-L1 are a general predictor of neoadjuvant therapy response. In an exploratory analysis, we identified seven genes that were higher expressed in responders in the durvalumab arm, but not the placebo arm: HLA-A, HLA-B, TAP1, GBP1, CXCL10, STAT1, and CD38. These genes were associated with cellular antigen processing and presentation and IFN signaling. Immune-associated signatures are associated with pCR after chemotherapy, but might be of limited use for the prediction of response to additional immune checkpoint blockade. Gene expressions related to antigen presentation and IFN signaling might be interesting candidates for further evaluation.

Usage metrics

    Clinical Cancer Research





    Ref. manager